Operating revenues and cash flow improved year-over-year, but profitability was impacted by higher costs, a NOK 337 million impairment on Alginor, and non-recurring expenses. Segment results were mixed, with Fine Chemicals and BioMaterials up, but BioSolutions down. Equity ratio remains strong at 5…
Operating revenues and cash flow improved year-over-year, but profitability was impacted by higher costs, a NOK 337 million impairment on Alginor, and non-recurring expenses. Segment results were mixed, with Fine Chemicals and BioMaterials up, but BioSolutions down. Equity ratio remains strong at 59.0%.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
